hVIVO (LON:HVO) Stock Price Up 13% - Here's What Happened

Key Points

• Shares of hVIVO plc increased by 13%, reaching GBX 7.80 ($0.10), with trading volume surging by 223% compared to its average daily volume.
• Analysts have issued mixed ratings for hVIVO, with two analysts maintaining a "Buy" rating, while Shore Capital reduced their price target from GBX 35 to GBX 25.
• hVIVO reported a net margin of 25.96% and a return on equity of 47.93%, with earnings per share for the latest quarter at GBX (0.29).

Shares of hVIVO plc (LON:HVO - Get Free Report) rose 13% on Tuesday . The stock traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). Approximately 9,588,585 shares changed hands during mid-day trading, an increase of 223% from the average daily volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Wall Street Analysts Forecast Growth

HVO has been the subject of several research analyst reports. Shore Capital decreased their price objective on hVIVO from GBX 35 to GBX 25 and set a "buy" rating for the company in a report on Tuesday, September 23rd. Peel Hunt reaffirmed an "add" rating and set a GBX 21 price target on shares of hVIVO in a report on Tuesday, July 29th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, hVIVO has an average rating of "Buy" and an average price target of GBX 23.

hVIVO Trading Up 2.4%

The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company has a fifty day moving average of GBX 9.24 and a two-hundred day moving average of GBX 11.96. The stock has a market capitalization of £54.91 million, a price-to-earnings ratio of 1,037.66 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, research analysts expect that hVIVO plc will post 1.5492958 EPS for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.